JAK2 and myeloproliferative neoplasm: In this regard, it is worth noting that ruxolitinib exerts modest effects on depleting MPN cells and reducing the JAK2‐V617F mutant allele burden in MPN patients (only 10%–20% reduction) and also showed little effects on disease progression to post‐MPN sAML.54, 55